Sirius Therapeutics Partners with CRISPR Therapeutics to Develop SRSD107 for Thrombosis
Sino-US biotech Sirius Therapeutics has entered into a partnership with Swiss–American biotech CRISPR Therapeutics (NASDAQ:...
NASDAQ: CRSP
FDA Approves Casgevy, the First CRISPR-Based Gene Editing Therapy for β-Thalassemia
Casgevy (exagamglogene autotemcel), the pioneering gene editing therapy based on CRISPR technology, has received approval...
Vertex Pharmaceuticals and CRISPR Therapeutics Receive Conditional Approval for CRISPR Gene-Editing Therapy
Vertex Pharmaceuticals (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) have received conditional approval from the...